BLAINJECTIONINJECTABLE
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
5/8 — Partial
CINQAIR (reslizumab) by Teva is interleukin-5 antagonists [moa]. First approved in 2016.
Drug data last refreshed 8h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINQAIR (reslizumab) is a monoclonal antibody that targets interleukin-5 (IL-5), a key cytokine driving eosinophilic inflammation. It is indicated for severe asthma with an eosinophilic phenotype in adult patients. The drug works by blocking IL-5 signaling, reducing eosinophil recruitment and activation in the airways.
$0.956MPart D
PeakPeak-stage product with modest Part D penetration (243 claims in 2023) suggests a niche, mature market with stable but limited team expansion.
Mechanism of Action
Interleukin-5 Antagonists
Pharmacologic Class:
Interleukin-5 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
Started Feb 2021
10 enrolled
Asthma; Eosinophilic
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Started Sep 2017
10 enrolled
Asthma
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Started May 2017
5 enrolled
Asthma
Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
Started Apr 2017
30 enrolled
Severe Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Started Mar 2017
391 enrolled
Eosinophils, Asthma
Worked on CINQAIR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.